Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
Vertex Pharmaceuticals raised its annual revenue forecast on Monday after reporting better-than-expected third-quarter earnings, driven by strong demand for its cystic fibrosis treatments. The company's product revenue increased 12% year-over-year to $2.77 billion, surpassing analysts' estimates. Adjusted earnings per share came in at $3.89, exceeding expectations. Vertex raised its full-year revenue guidance to between $10.8 billion and $10.9 billion. The company noted that third-quarter revenue included income from the first patient infused with CASGEVY.
Vertex Pharmaceuticals raised its annual revenue forecast on Monday after it beat third-quarter estimates on demand for its cystic fibrosis (CF) treatments. https://t.co/9ksDDgJPhs https://t.co/9ksDDgJPhs
NXP tumbles on weak outlook as automotive chip revenues decline https://t.co/0sxR7fW3vR
$BAM Brookfield Asset Management Ltd. just held the company's Q3 2024 earnings call. ๐๏ธ Insights for $BAM investors: ๐๐๐ 1. Strong Financial Performance: - Record fee-related earnings of $644M ($0.39 per share), up 14% year-over-year - Fee-bearing capital grew 23% to $539B -โฆ
